One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs
Locally advanced microsatellite instability-high esophagogastric cancer: are we ready to change our treatment paradigm?
Unravelling lung adenocarcinoma with mucinous histology and its translational implications
Is the abundance of B cells the best biomarker to predict immune checkpoint inhibitor response in head and neck squamous cell cancers?
The best management for most patients with incurable cancer is on a clinical trial
Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
Long-term outcomes in the PRIMA trial: a closer look at progression-free survival and overall survival
Reply to Letter to the Editor ‘Long-term outcomes in the PRIMA trial: a closer look at PFS and OS’ by Wu et al.
Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline
Letter to the Editor regarding ‘Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies’ by G Liu et al.
Reply to Letter to the Editor regarding “Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies� by C. Zhang
Six-year duration of adjuvant imatinib in high-risk GIST: more to come
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
Corrigendum to “Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023�: [Annals of Oncology 34 (2023) 970-986]
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma�: [Ann Oncol 35 (2024) 1039-1047]
